Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Janice Mehnert

Janice Mehnert

NYU Grossman School of Medicine

Incorporating neoadjuvant immunotherapies in rare skin cancers

Incorporating neoadjuvant immunotherapies in rare skin cancers

Janice Mehnert • 11 Nov 2025

Comparing the role of adjuvant IO in Merkel cell carcinoma and melanoma

Comparing the role of adjuvant IO in Merkel cell carcinoma and melanoma

Janice Mehnert • 11 Nov 2025

STAMP: adjuvant pembrolizumab in resected Merkel cell carcinoma

STAMP: adjuvant pembrolizumab in resected Merkel cell carcinoma

Janice Mehnert • 11 Nov 2025

Adding sarilumab to checkpoint inhibitors improves melanoma response and reduces toxicity

Adding sarilumab to checkpoint inhibitors improves melanoma response and reduces toxicity

Janice Mehnert • 22 Jul 2025

The future of sarilumab with checkpoint inhibition in unresectable melanoma

The future of sarilumab with checkpoint inhibition in unresectable melanoma

Janice Mehnert • 9 Jul 2025

Phase II trial of sarilumab and checkpoint inhibition in stage III/IV melanoma

Phase II trial of sarilumab and checkpoint inhibition in stage III/IV melanoma

Janice Mehnert • 3 Jun 2025

The growing role of cellular therapy in NRAS-mutant melanoma

The growing role of cellular therapy in NRAS-mutant melanoma

Janice Mehnert • 25 Nov 2024

The potential of rechallenging the RAF pathway with NRAS inhibitors in melanoma

The potential of rechallenging the RAF pathway with NRAS inhibitors in melanoma

Janice Mehnert • 25 Nov 2024

Importance of pan-RAF inhibitors in the future of melanoma treatment

Importance of pan-RAF inhibitors in the future of melanoma treatment

Janice Mehnert • 20 Nov 2024

Results from a Phase I trial evaluating exarafenib in NRAS-mutant melanoma

Results from a Phase I trial evaluating exarafenib in NRAS-mutant melanoma

Janice Mehnert • 20 Nov 2024